Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBT Margin (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed EBT Margin for 9 consecutive years, with 19.5% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 2955.0% to 19.5% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.58% through Dec 2025, up 4176.0% year-over-year, with the annual reading at 1.58% for FY2025, 4176.0% up from the prior year.
  • EBT Margin for Q4 2025 was 19.5% at Akebia Therapeutics, down from 1.97% in the prior quarter.
  • The five-year high for EBT Margin was 7370.05% in Q2 2022, with the low at 5868.5% in Q4 2021.
  • Average EBT Margin over 5 years is 15.59%, with a median of 53.54% recorded in 2024.
  • The sharpest move saw EBT Margin surged 752937bps in 2022, then crashed -738987bps in 2023.
  • Over 5 years, EBT Margin stood at 5868.5% in 2021, then soared by 96bps to 216.83% in 2022, then soared by 84bps to 34.46% in 2023, then plummeted by -42bps to 49.04% in 2024, then skyrocketed by 60bps to 19.5% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 19.5%, 1.97%, and 0.4% for Q4 2025, Q3 2025, and Q2 2025 respectively.